These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15840410)

  • 1. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
    Nakamura H; Inoue T; Arakawa N; Shimizu Y; Yoshigae Y; Fujimori I; Shimakawa E; Toyoshi T; Yokoyama T
    Eur J Pharmacol; 2005 Apr; 512(2-3):239-46. PubMed ID: 15840410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
    Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
    Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
    Nussberger J; Koike H
    Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
    Mizuno M; Sada T; Kato M; Koike H
    Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
    Nagisa Y; Shintani A; Nakagawa S
    Diabetologia; 2001 Jul; 44(7):883-8. PubMed ID: 11508274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
    Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
    Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ameliorative effects on retinal disorder in diabetic SHRSP (stroke-prone spontaneously hypertensive rat)].
    Nagisa Y; Shintani A; Nakagawa S
    Nihon Rinsho; 2002 Oct; 60(10):1975-80. PubMed ID: 12397694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression.
    Jia N; Okamoto H; Shimizu T; Chiba S; Matsui Y; Sugawara T; Akino M; Kitabatake A
    Hypertens Res; 2003 Sep; 26(9):737-42. PubMed ID: 14620930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
    Koike H; Sada T; Mizuno M
    J Hypertens Suppl; 2001 Jun; 19(1):S3-14. PubMed ID: 11451212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
    Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.
    Mire DE; Silfani TN; Pugsley MK
    J Cardiovasc Pharmacol; 2005 Nov; 46(5):585-93. PubMed ID: 16220064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
    Igase M; Yokoyama H; Ferrario CM
    Ther Adv Cardiovasc Dis; 2011 Dec; 5(6):297-304. PubMed ID: 22089474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
    Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
    Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
    Pugsley MK
    Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects.
    Kreutz R; Bolbrinker J; Huber M
    Clin Drug Investig; 2006; 26(1):29-34. PubMed ID: 17163232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
    Nakamoto T; Harasawa H; Akimoto K; Hirata H; Kaneko H; Kaneko N; Sorimachi K
    Eur J Pharmacol; 2005 Dec; 528(1-3):43-51. PubMed ID: 16336959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
    Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
    Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.
    Igase M; Kohara K; Nagai T; Miki T; Ferrario CM
    Hypertens Res; 2008 Mar; 31(3):553-9. PubMed ID: 18497476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
    Paulis L; Becker ST; Lucht K; Schwengel K; Slavic S; Kaschina E; Thöne-Reineke C; Dahlöf B; Baulmann J; Unger T; Steckelings UM
    Hypertension; 2012 Feb; 59(2):485-92. PubMed ID: 22215717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.